Nightingale to open US preventive health lab

Company partners with precision medicine institute to power precision metabolomics with blood analysis technology.

Finnish preventive health company Nightingale Health has revealed plans to establish a laboratory in the US, bringing its health risk detection technologies to North America. The company has formed a strategic partnership with the Englander Institute for Precision Medicine at Weill Cornell Medicine, which will see Nightingale Health’s proprietary technology integrated into the institute’s operations.

The Englander Institute has a rich history of leveraging innovative technologies to personalize disease research, treatment and prevention. The new collaboration aims to harness the power of Nightingale’s advanced blood analysis technology, including multi-disease risk prediction models and individual diagnostic biomarkers, to enhance the institute’s clinical services and research capabilities. The exact location and opening schedule of the new laboratory are yet to be announced.

“Our precision metabolomics pilot project marks the beginning of a new era in healthcare,” said Olivier Elemento, Director of Englander Institute of Precision Medicine. “The vision is to use metabolic profiling to tailor treatments uniquely for each patient, advancing precision medicine to benefit patients globally.”

Nightingale’s approach uses nuclear magnetic resonance spectroscopy to analyze blood samples, producing up to 250 times more molecular health data from one sample compared to a regular blood test, and providing a “comprehensive picture of human metabolism.” According to the company, generating the same set of results using traditional methods would require several tests.

Founded with a vision to empower individuals to prioritize their health and well-being, Nightingale provides a scientific framework to predict and prevent myriad health conditions. The company’s expansion into the US builds upon its existing global footprint, with subsidiaries spanning across various countries, including Japan, Singapore and the United Kingdom.

“The collaboration with Englander Institute for Precision Medicine at Weill Cornell Medicine will explore and implement ways for comprehensive risk assessment from our unique blood testing technology for patient treatment, health checks and screening programs for multiple common chronic diseases,” said Teemu Suna, Nightingale Health’s CEO and Founder.

Photograph courtesy of Nightingale Health